Oncologie | Newsroom

newsroom

Oncologie, Inc. Announces Collaboration with Moffitt Cancer Center to Advance the Development of Precision Medicine for the Treatment of Gastric and Gastrointestinal Cancers

Press Release | February 25, 2020 | Source: Oncologie Waltham, MA. February 25, 2020 — Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment (TME), announced today that it has entered into a collaboration agreement with Moffitt Cancer Center. The collaboration......
Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Cancer

Press Release | January 22, 2020 | Source: Genialis Leading biosciences companies will model patient data to further evaluate biomarkers in immuno-oncology studies SAN RAMON, Calif. & WALTHAM, Mass.–(BUSINESS WIRE)–Genialis, a leader in applied data science for the development of precision medicines, today announced a collaborative......
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab

Press Release | January 13, 2020 | Source: Oncologie Oncologie receives exclusive global license to develop and commercialize navicixizumab London, Redwood City, Calif., and Boston, January 13, 2020 – Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company,” and Oncologie, Inc. (“Oncologie”) today announced......
Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

Press Release | October 09, 2019 | Source: Oncologie – The initiated study will further evaluate the antitumor activity, safety and tolerability of bavituximab plus KEYTRUDA® in a gastric cancer population – Oncologie’s first global study for bavituximab plans enrollment in the US, UK, Taiwan and......

Oncologie Closes an $80M Series B Financing for Clinical-Stage Pipeline

Press Release | June 10, 2019 | Source: Oncologie BOSTON, June 10, 2019 — Oncologie, an innovative biopharmaceutical company using proprietary biomarkers to drive clinical development of next-generation oncology therapeutics, announced today that it has closed an $80M Series B financing. Existing investors, led by Nan Fung Life......
HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

Press Release | August 03, 2018 | Source: HTG Molecular Diagnostics, Inc. TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with......
Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China

News Article | June 07, 2018 | Source: Oncologie, Inc. BOSTON and SHANGHAI, June 7, 2018 /PRNewswire/ — Oncologie, an innovative biopharmaceutical company, announced today that it is launching operations in both Boston and Shanghai with $16.5M seed financing led by Pivotal bioVenture Partners China. Oncologie is......
MOLOGEN Signs License Deal for China and Global Co-Development Agreement with Oncologie for Lead Compound lefitolimod

Press Release | February 13, 2018 | Source: Mologen BERLIN–(BUSINESS WIRE)–The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today the signing of a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for......

Oncologie, Inc. Announces Collaboration with Moffitt Cancer Center to Advance the Development of Precision Medicine for the Treatment of Gastric and Gastrointestinal Cancers

Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Cancer

Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

Oncologie Closes an $80M Series B Financing for Clinical-Stage Pipeline

HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China

MOLOGEN Signs License Deal for China and Global Co-Development Agreement with Oncologie for Lead Compound lefitolimod

Menu

Copyright